VIEW WEBSITE >>

Leeds, GB · 1 known investors

LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.

BiotechHealthtechMedical Devices